Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03339297 · ClinicalTrials.gov registry record · Phase 2
An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)
A Phase 2 study, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 152
- Enrollment target
NCT03339297 is a Phase 2 study that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 152 participants.
The verdict
NCT03339297, a Phase 2 study, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 152 participants
- Enrollment target
Study Summary
This is a study comparing the defibrotide prophylaxis arm vs standard of care arm for the prevention of aGvHD.
Interventions
- DRUG Standard of Care
- DRUG Defibrotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2018-02-21 |
| Est. Completion | 2020-05-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03339297
The ClinicalTrials.gov registry entry for NCT03339297 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 152 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT03339297 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03339297 about?
NCT03339297 is a clinical study titled "An Open-Label Study of Defibrotide for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)". This is a study comparing the defibrotide prophylaxis arm vs standard of care arm for the prevention of aGvHD.
What is the current status of trial NCT03339297?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 152 participants. The study started on 2018-02-21. Estimated completion is 2020-05-12.
What interventions are being tested in trial NCT03339297?
The interventions under investigation include: Standard of Care (DRUG), Defibrotide (DRUG).
Who is sponsoring clinical trial NCT03339297?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.